PE20000644A1 - Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea - Google Patents
Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroideaInfo
- Publication number
- PE20000644A1 PE20000644A1 PE1999000526A PE00052699A PE20000644A1 PE 20000644 A1 PE20000644 A1 PE 20000644A1 PE 1999000526 A PE1999000526 A PE 1999000526A PE 00052699 A PE00052699 A PE 00052699A PE 20000644 A1 PE20000644 A1 PE 20000644A1
- Authority
- PE
- Peru
- Prior art keywords
- reconstruction
- estrogen receptor
- parathyroid hormone
- receptor modulator
- selective estrogen
- Prior art date
Links
- 229940095743 selective estrogen receptor modulator Drugs 0.000 title abstract 3
- 239000000333 selective estrogen receptor modulator Substances 0.000 title abstract 3
- 102000003982 Parathyroid hormone Human genes 0.000 title abstract 2
- 108090000445 Parathyroid hormone Proteins 0.000 title abstract 2
- 239000000199 parathyroid hormone Substances 0.000 title abstract 2
- 229960001319 parathyroid hormone Drugs 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010065687 Bone loss Diseases 0.000 abstract 2
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001815 facial effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical class OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 230000003387 muscular Effects 0.000 abstract 1
- 201000001245 periodontitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
SE REFIERE A UNA COMPOSICION QUE COMPRENDE a)UN MODULADOR DEL RECEPTOR DE ESTROGENOS SELECTIVO (SERM) TAL COMO (-)-CIS-6-FENIL-5-(4-(2-PIRROLIDIN-1-IL-ETOXI)-FENIL-5,6,7,8-TETRAHIDRONAFTALEN-2-OL O SU SAL D-TARTRATO; b)UN COMPUESTO DE HORMONA PARATIROIDEA O SUS FRAGMENTOS BIOLOGICAMENTE ACTIVOS. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE OSTEOPOROSIS, OSTEOTOMIA, PERDIDA OSEA IDIOPATICA DE LA INFANCIA O PERDIDA OSEA ASOCIADA A PERIODONTITIS, O PARA TRATAR UNA FRACTURA OSEA O CURACION OSEA DESPUES DE UNA RECONSTRUCCION FACIAL, RECONSTRUCCION MAXILAR, RECONSTRUCCION MANDIBULAR, FRAGILIDAD MUSCULOESQUELETICA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8947998P | 1998-06-16 | 1998-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000644A1 true PE20000644A1 (es) | 2000-08-02 |
Family
ID=22217879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000526A PE20000644A1 (es) | 1998-06-16 | 1999-06-14 | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6132774A (es) |
| EP (1) | EP1094808A1 (es) |
| JP (1) | JP2002518323A (es) |
| KR (1) | KR20010052818A (es) |
| CN (1) | CN1305373A (es) |
| AP (1) | AP9901580A0 (es) |
| AR (1) | AR018867A1 (es) |
| AU (1) | AU3725999A (es) |
| BG (1) | BG105125A (es) |
| BR (1) | BR9911228A (es) |
| CA (1) | CA2335078A1 (es) |
| CO (1) | CO5070584A1 (es) |
| EA (1) | EA200001199A1 (es) |
| GT (1) | GT199900066A (es) |
| HN (1) | HN1999000063A (es) |
| HR (1) | HRP20000858A2 (es) |
| HU (1) | HUP0102759A3 (es) |
| ID (1) | ID26873A (es) |
| IL (1) | IL139588A0 (es) |
| IS (1) | IS5719A (es) |
| MA (1) | MA26649A1 (es) |
| NO (1) | NO20006313L (es) |
| NZ (1) | NZ508039A (es) |
| OA (1) | OA11566A (es) |
| PA (1) | PA8471201A1 (es) |
| PE (1) | PE20000644A1 (es) |
| PL (1) | PL344982A1 (es) |
| SK (1) | SK18922000A3 (es) |
| TN (1) | TNSN99119A1 (es) |
| TR (1) | TR200003567T2 (es) |
| UA (1) | UA60367C2 (es) |
| WO (1) | WO1999065482A1 (es) |
| YU (1) | YU75800A (es) |
| ZA (1) | ZA993972B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| US20020107230A1 (en) * | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
| US20030191096A1 (en) * | 2002-04-03 | 2003-10-09 | Leonard Thomas W. | Method of hormonal therapy |
| JP2007512359A (ja) | 2003-11-19 | 2007-05-17 | メタバシス・セラピューティクス・インコーポレイテッド | 新規なリン含有甲状腺ホルモン様物質 |
| MX2007005137A (es) * | 2004-11-23 | 2007-06-22 | Warner Lambert Co | Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia. |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7919506B2 (en) | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| US20120046364A1 (en) | 2009-02-10 | 2012-02-23 | Metabasis Therapeutics, Inc. | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use |
| TW201043595A (en) * | 2009-03-13 | 2010-12-16 | Organon Nv | Tetrahydronaphthalen-2-ol derivatives |
| DE102010027016A1 (de) | 2010-07-09 | 2012-01-12 | Universitätsklinikum Jena | Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen |
| CN111067907A (zh) * | 2018-10-18 | 2020-04-28 | 常州大学 | 孕激素在抑制血管内皮生长因子表达中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254595A (en) * | 1988-12-23 | 1993-10-19 | Elf Sanofi | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
-
1999
- 1999-04-29 PA PA19998471201A patent/PA8471201A1/es unknown
- 1999-05-03 HN HN1999000063A patent/HN1999000063A/es unknown
- 1999-05-10 GT GT199900066A patent/GT199900066A/es unknown
- 1999-05-26 WO PCT/IB1999/000949 patent/WO1999065482A1/en not_active Ceased
- 1999-05-26 JP JP2000554362A patent/JP2002518323A/ja active Pending
- 1999-05-26 NZ NZ508039A patent/NZ508039A/xx unknown
- 1999-05-26 OA OA1200000340A patent/OA11566A/en unknown
- 1999-05-26 CA CA002335078A patent/CA2335078A1/en not_active Abandoned
- 1999-05-26 UA UA2000127244A patent/UA60367C2/uk unknown
- 1999-05-26 IL IL13958899A patent/IL139588A0/xx unknown
- 1999-05-26 BR BR9911228-0A patent/BR9911228A/pt not_active IP Right Cessation
- 1999-05-26 PL PL99344982A patent/PL344982A1/xx unknown
- 1999-05-26 AU AU37259/99A patent/AU3725999A/en not_active Abandoned
- 1999-05-26 HR HR20000858A patent/HRP20000858A2/hr not_active Application Discontinuation
- 1999-05-26 KR KR1020007014141A patent/KR20010052818A/ko not_active Ceased
- 1999-05-26 CN CN99807345A patent/CN1305373A/zh active Pending
- 1999-05-26 TR TR2000/03567T patent/TR200003567T2/xx unknown
- 1999-05-26 YU YU75800A patent/YU75800A/sh unknown
- 1999-05-26 SK SK1892-2000A patent/SK18922000A3/sk unknown
- 1999-05-26 ID IDW20002626A patent/ID26873A/id unknown
- 1999-05-26 EA EA200001199A patent/EA200001199A1/ru unknown
- 1999-05-26 HU HU0102759A patent/HUP0102759A3/hu unknown
- 1999-05-26 US US09/424,010 patent/US6132774A/en not_active Expired - Fee Related
- 1999-05-26 EP EP99919491A patent/EP1094808A1/en not_active Withdrawn
- 1999-06-10 AP APAP/P/1999/001580A patent/AP9901580A0/en unknown
- 1999-06-14 PE PE1999000526A patent/PE20000644A1/es not_active Application Discontinuation
- 1999-06-15 ZA ZA9903972A patent/ZA993972B/xx unknown
- 1999-06-15 AR ARP990102846A patent/AR018867A1/es not_active Application Discontinuation
- 1999-06-15 MA MA25623A patent/MA26649A1/fr unknown
- 1999-06-15 TN TNTNSN99119A patent/TNSN99119A1/fr unknown
- 1999-06-16 CO CO99037623A patent/CO5070584A1/es unknown
-
2000
- 2000-11-21 IS IS5719A patent/IS5719A/is unknown
- 2000-12-12 NO NO20006313A patent/NO20006313L/no not_active Application Discontinuation
-
2001
- 2001-01-08 BG BG105125A patent/BG105125A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000644A1 (es) | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea | |
| ES2055845T3 (es) | Composicion farmaceutica para el tratamiento de la osteoporosis. | |
| AR023130A1 (es) | Composiciones para promover el crecimiento | |
| BR0211932A (pt) | Métodos e composições para administração oral de hormÈnio de paratireóide, pth | |
| BR0308355A (pt) | Composto ou um sal farmaceuticamente aceitável ou um seu enanciÈmero, métodos para modular uma função mediada pelo receptor de androgênio em um mamìfero em necessidade de tal modulação, para ativar a função do receptor de androgênio em um mamìfero em necessidade de tal ativação, para tratar uma condição em um mamìfero, e para tratar osteoporose em um mamìfero em sua necessidade, composição farmacêutica, métodos para aumentar a densidade mineral óssea em um mamìfero em necessidade disto, para reduzir o risco de fraturas vertebrais ou não vertebrais em um mamìfero em necessidade disto, e para produzir um marcador de modificação óssea em um mamìfero em necessidade disto, processo para produzir uma composição farmacêutica, e, método para tratar ou prevenir uma condição artrìtica em um mamìfero em necessidade disto | |
| DE59810425D1 (de) | Markraumnagel zur operativen behandlung von unterarmfrakturen | |
| ES2179319T3 (es) | Acido linoleico conjugado para mantener o aumentar el contenido de minerales de los huesos. | |
| MXPA02005173A (es) | Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea. | |
| ATE112684T1 (de) | Verwendung von igf-ii zur behandlung von knochenkrankheiten. | |
| BRPI0417621A (pt) | terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea | |
| ES2116642T3 (es) | Composicion farmaceutica para tratar la osteoporosis que contiene xantohumol. | |
| BG106118A (en) | Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit | |
| ATE289293T1 (de) | Substituierte aminoalkylamid-derivate als antagonisten des follikel-stimulierenden hormons | |
| DK1677806T3 (da) | Sammensætninger til behandling af akut og overbelastningsforårsaget forstuvning og forstrækning ved anvendelse af hyaluronsyre | |
| NO20060498L (no) | Metode for a promotere benvekst | |
| NZ598370A (en) | Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units | |
| BRPI0407178A (pt) | Composição farmacêutica osteogênica | |
| PE20000633A1 (es) | Combinaciones terapeuticas para la fragilidad musculoesqueletica | |
| WO2001080894A3 (en) | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies | |
| PE20000646A1 (es) | Terapia de combinacion para la fragilidad musculoesqueletica | |
| BR0314362A (pt) | Método para previnir ou reduzir fraturas secundárias após fratura de quadril | |
| BRPI0416933A (pt) | composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e, métodos para aumentar a respiração mitocondrial em um paciente, e para reduzir a quantidade de espécies de oxigênio reativas em um paciente | |
| BR0013416A (pt) | Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado | |
| GB9903598D0 (en) | Connective tissue healing | |
| TW200509955A (en) | Pharmaceutical composition for prophylaxis or treatment of osteoporosis, and method to prepare the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |